Biotech Values

[DewDiligence]

RIGL +35% on successful (first) phase-3 in ITP:

http://finance.yahoo.com/news/rigels-fostamatinib-meets-primary-endpoint-110000198.html

Rigel Pharmaceuticals, Inc. today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP). The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261). A stable platelet response was defined as achieving greater than 50,000 platelets per uL of blood on at least four of the last six scheduled visits between weeks 14 and 24 of treatment.

The results from the second FIT Phase 3 study are expected in October/November 2016.